Currently there are no treatments available for osteoarthritis (OA). In order to establish new therapeutic strategies for the treatment of OA, a better understanding of the cellular and molecular changes during OA progression is required. The progressive ankylosis protein (ANK) is a transmembrane protein that transports intracellular pyrophosphate (PPi) to the extracellular milieu. (1) Previous studies have shown that extracellular PPi and inorganic phosphate (Pi) resulting from PPi hydrolysis affect cartilage calcification as well as chondrocyte differentiation. (2, 3) Extracellular PPi has been shown to inhibit basic calcium phosphate (BCP) crystal formation. However, excessive extracellular PPi concentrations lead to the formation of calcium pyrophosphate (CPPD) crystals. (4, 5) Both types of crystals are found in human OA patients. In addition, several lines of evidence suggest that ANK via its cytoplasmic N-terminal and C-terminal domains interacts with other proteins and these interactions may modulate signaling pathway activities. (6) Since ANK expression is low in normal healthy articular cartilage and its expression levels increase in OA pathology, we have determined the role of ANK in OA pathology. (7, 8) 
in ank/ank cells compared with wild type cells. Over-expression of ANK in human articular chondrocytes resulted in increased luciferase activity from the NF-κB reporter and increased MMP-13 mRNA levels in the absence or presence of IL-1 compared with empty vector-transfected human cells.
Since ANK is a transmembrane protein that transports intracellular PPi to the extracellular milieu, (1) we also determined the role of extracellular PPi on articular chondrocyte function and phenotype. Since extracellular PPi is hydrolyzed into Pi by APase, we cultured human articular chondrocytes in the presence of PPi and in the presence or absence of levamisole, a specific inhibitor of APase. In the absence of levamisole, when most of extracellular PPi is hydrolyzed into Pi, MMP-13 and hypertrophic marker mRNA levels were increased, while articular cartilage marker mRNA levels were decreased compared with the mRNA levels of these genes in untreated cells. In the presence of levamisole, PPi treatment resulted in increased articular chondrocyte marker mRNA levels, whereas hypertrophic marker and MMP-13 mRNA levels were decreased compared with the levels of these genes in untreated cells. However, treatment of human articular chondrocytes with PPi and levamisole resulted in CPPD crystal formation. Since bisphosphonates are non-hydrolysable PPi analogues that, similar to PPi, inhibit BCP crystal formation but do not lead to CPPD crystal formation, we determined whether the bisphosphonate zolendronate may be a novel treatment modality to slow down cartilage destruction during OA pathology. Treatment of human articular chondrocytes with zolendronate resulted in decreased MMP-13 and hypertrophic marker mRNA levels and increased articular chondrocyte marker mRNA levels in the absence or presence of IL-1.
DISCUSSION:
ANK expression markedly increases during OA progression. (7, 8) Here we demonstrate that increased ANK expression in OA cartilage acts catabolically on articular cartilage and increases cartilage destruction during OA pathology. Our findings reveal that the catabolic events of increased ANK expression in articular chondrocytes result from different mechanisms: (a) the activation of NF-κB by preventing the shuttling of MYBBP1a into the nucleus where it inhibits NF-κB and potentially other mechanisms; (b) the extracellular Pi resulting from the hydrolysis of increased extracellular PPi levels stimulates hypertrophic changes and MMP-13 expression; (c) the potential BCP and/or CPPD crystal formation resulting from increased extracellular Pi and PPi concentrations. On the other hand, our results reveal that extracellular PPi inhibited MMP-13 mRNA levels and hypertrophic changes of articular chondrocytes. Consequently, zolendronate, a non-hydrolysable analogue of PPi, inhibited MMP-13 expression and hypertrophic changes of articular chondrocytes and increased aggrecan and type II collagen expression. In conclusion, ANK stimulates hypertrophic differentiation, mineralization, NF-κB activity, and MMP-13 expression in chondrocytes during OA pathology, whereas bisphosphonates as nonhydrolysable PPi analogues protect articular cartilage function and phenotype.
SIGNIFICANCE:
The understanding of the mechanisms of how ANK affects articular chondrocyte function and phenotype during OA pathology may lead to the discovery of novel therapeutic targets for the treatment of OA.
